Arena Pharmaceuticals Inc (NASDAQ:ARNA) EVP Steven W. Spector sold 45,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.26, for a total transaction of $281,700.00. Following the transaction, the executive vice president now directly owns 128,039 shares in the company, valued at approximately $801,524.14. On Tuesday shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed at $6.05. Company’s sales growth for last 5 years was 52.70%.
Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, announced that it expects to report revenue for the fourth quarter of 2014 in the range of $13.2 to $13.4 million, an increase of approximately 91% over the fourth quarter of 2013, and for the year ended December 31, 2014 in the range of $38.4 to $38.6 million. Intersect ENT, Inc. (NASDAQ:XENT) in last trading activity moved up 22.29% to close at $23.04. Company weekly performance is 13.89% while its quarterly performance stands at 41.78%. Intersect ENT, Inc. (NASDAQ:XENT) is 7.71% away from its 52 week high.
The biotech sector continues to witness mergers and acquisitions. Earlier this week, Biogen Idec (NASDAQ:BIIB) announced its intention to acquire U.K.-based Convergence Pharmaceuticals, a clinical stage biopharmaceutical company with a focus on developing treatments for neuropathic pain. On Tuesday shares of Biogen Idec Inc. (NASDAQ:BIIB) closed at $352.74. Company’s sales growth for last 5 years was 11.10% and EPS growth for next 5 years is recorded as 23.40%.
Albemarle Corporation (NYSE:ALB) announced that it has completed its acquisition of Rockwood Holdings, Inc. (NYSE:ROC) pursuant to the terms of their previously announced Agreement and Plan of Merger dated as of July 15, 2014 (the “Merger Agreement”). Rockwood Holdings, Inc. (NYSE:ROC) has 1.20% insider ownership while its institutional ownership stands at 96.70%. In last trading activity company’s stock closed at $79.20.
NuVasive, Inc. (NASDAQ:NUVA), provided a business and financial performance update, including the announcement of select preliminary unaudited financial results for the full-year ended December 31, 2014 and the issuance of select performance guidance for the full-year 2015. Preliminary full-year 2014 revenue of approximately $761 million; reflects 11% growth over the prior year, or 12% on a constant currency basis. Preliminary full-year 2014 non-GAAP operating margin anticipated to exceed guidance of 16.5%. On last trading day NuVasive, Inc. (NASDAQ:NUVA) fell -3.51% to close at $47.61. Its volatility for the week is 3.22% while volatility for the month is 2.94%. NUVA’s sales growth for past 5 years was 22.30% and its EPS growth for past 5 years was 17.30%. NuVasive, Inc. (NASDAQ:NUVA) monthly performance is 2.43%.